

Report on global sexually transmitted infection surveillance

2018



Report on global sexually transmitted infection surveillance, 2018



Report on global sexually transmitted infection surveillance, 2018

ISBN 978-92-4-156569-1

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Report on global sexually transmitted infection surveillance, 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

Contents

Acknowledgments	iv
Abbreviations and acronyms	v
Executive summary	vii
1. Introduction	1
1.1 The global health sector strategy on STIs 2016–2021	2
1.2 Data systems and tools for STI surveillance	5
1.3 Overall data quality and considerations for interpretation	5
2. Towards elimination of mother-to-child transmission of syphilis	7
2.1 Monitoring the ANC syphilis testing and treatment cascade	9
2.2 ANC syphilis data quality and interpretation	11
2.3 Country validation of EMTCT of syphilis and HIV	18
3. Prevalence of syphilis among key populations	19
3.1 Data quality and interpretation	20
4. Case reporting for urethral discharge and gonorrhoea in the general population	23
4.1 Data quality and interpretation	24
4.2 Syndromic case reporting	24
4.3 Etiological case reporting	26
5. Estimating prevalence trends for chlamydia, gonorrhoea and syphilis using epidemic models	29
6. Gonococcal antimicrobial susceptibility	33
6.1 Gonococcal Antimicrobial Surveillance Programme (GASP)	33
6.2 Antimicrobial susceptibility data	35
6.3 Data quality and interpretation	37
7. Human papillomavirus vaccination to prevent cervical cancer	38
8. Conclusion	41
Annexes	43
Annex 1. Cascade of indicators for elimination of mother-to-child transmission (EMTCT) of syphilis using the most recent data reported through the Global AIDS Response Progress Reporting (GARPR) system, 2008–2017	43
Annex 2. Syphilis prevalence reported for female sex workers and MSM using the most recent data reported through the Global AIDS Response Progress Reporting (GARPR) system, 2008–2017	48
Annex 3. Reported cases of urethral discharge (UD) in men (cases per 100 000 adult males), based on the most recent data reported through the Global AIDS Monitoring (GAM) system, 2014–2017	51
Annex 4. Gonorrhoea rates among men (cases per 100 000 adult men) based on the most recent data reported through the Global AIDS Response Progress Reporting (GARPR) system, 2013–2017	53
Annex 5. Reported percentage of gonococcal isolates with resistance to azithromycin and ciprofloxacin/quinolones and elevated minimum inhibitory concentrations (MICs) of cefixime (>0.25 µg/mL) or ceftriaxone (>0.125 µg/mL), 2015 and 2016	55
References	58

Acknowledgments

The World Health Organization would like to thank Member States that work to collect and share data on the burden of sexually transmitted infections (STIs) in their countries. This report comprises the work of dedicated health-care providers at the local and national levels.

Melanie Taylor and Teodora Wi in the WHO Department of Reproductive Health and Research coordinated the development of the document. Sami Gottlieb, Igor Toskin, Paul Bloem and Nathalie Broutet contributed further inputs.

We would like to express our gratitude to the following WHO consultants: Virginia Loo who drafted this report; Eline Korenromp, Jane Rowley and Katherine Heath who contributed to the data and methods shared in this report; and Soe Soe Thwin who provided technical support for this work.

The Department acknowledges the support of WHO regional staff members on HIV and STI surveillance and programmes, including Monica Alonso Gonzalez, Maeve de Mello, Massimo Ghidinelli, Joumana Hermez, Ahmed Sabry, Naoko Ishikawa, Linh-Vi Le, Takeshi Nishijima, AnneMarie Stengaard, Bharat Rewari, Morkor Newman, Leopold Ouedrago, Ellen Thom, Saliyou Sanni and Innocent Nuwagira. We acknowledge and appreciate the specific input provided by additional technical experts during an STI regional stakeholders' meeting held on 30–31 January 2018.

We express gratitude to our colleagues in the Department of HIV/AIDS and UNAIDS for their support in collecting data through the Global AIDS Monitoring system (GAM), producing this report and strengthening STI surveillance: Maria Babovic, Michel Beusenberg, Jesus Maria Garcia Calleja, Gottfried Hirnschall, Daniel Low-Beer and Mary Mahy.

We also would like to thank our regional focal points and national partners of the WHO Gonococcal Antimicrobial Surveillance Programme (GASP): Michelle Cole, Jo Ann Dillon, Amina Hancali, Monic Lahra, Irene Martin, Pillar Ramon Pardo, Magnus Unemo, Hillard Weinstock and Emily Weston.

We express our appreciation for the financial support of the Department for International Development (DFID), United Kingdom and the United States Centers for Disease Control and Prevention (US CDC), and for the technical contributions of other colleagues dedicated to strengthening STI surveillance at the country, regional and global levels.

Abbreviations and acronyms

ABO	adverse birth outcome
AMR	antimicrobial resistance
ANC	antenatal care
EMTCT	elimination of mother-to-child transmission
ESC	extended-spectrum cephalosporins
FSW	female sex worker
GAM	Global AIDS Monitoring
GARPR	Global AIDS Response Progress Reporting
GASP	Gonococcal Antimicrobial Susceptibility Programme
GUD	genital ulcer disease
HPV	human papillomavirus
MIC	minimum inhibitory concentration
MSM	men who have sex with men
MTCT	mother-to-child transmission
NGO	nongovernmental organization
PID	pelvic inflammatory disease
PMTCT	prevention of mother-to-child transmission
PrEP	pre-exposure prophylaxis
PWID	people who inject drugs
RST	rapid syphilis test
SDGs	Sustainable Development Goals
STI	sexually transmitted infection
UD	urethral discharge
UI	uncertainty interval
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNPD	United Nations Population Division (of the Department of Economic and Social Affairs)
WHO	World Health Organization
XDR	extensively drug-resistant

Executive summary

Globally, more than 1 million curable sexually transmitted infections (STIs) occur each day. According to WHO global estimates for 2016, there were roughly 376 million new infections of the four curable STIs – chlamydia, gonorrhoea, syphilis and trichomoniasis.

STI prevention and control have widespread public health benefits and contribute to progress towards the Sustainable Development Goals (SDGs) related to ending preventable deaths of children under 5 years, combating communicable disease, and providing universal access to sexual and reproductive health care.

In 2016, WHO released its *Global health sector strategy on sexually transmitted infections 2016–2021*. The Strategy envisions that by 2030, rates of congenital syphilis will be reduced to less than 50 cases per 100 000 live births in 80% of countries; and the incidence of infections with *T. pallidum* (syphilis) and *N. gonorrhoeae* (gonorrhoea) would have fallen by 90% globally between 2018 and 2030.

To achieve its goals, a critical component of the Global STI Strategy is strengthening STI surveillance and programme monitoring systems. This report summarizes the latest country-reported data from Global AIDS Monitoring (GAM) and the Gonococcal Antimicrobial Susceptibility Programme (GASP) as well as regional- and country-level estimates generated using tools developed with support from WHO for modelling STI epidemics: Spectrum-STI and the WHO congenital syphilis estimation tool.

Towards elimination of mother-to-child transmission of syphilis

with few countries from high-burden regions reporting these values into GAM.

Syphilis prevalence among key populations

The seroprevalence of syphilis among key populations such as female sex workers (FSWs) and men who have sex with men (MSM) is an important indicator of progress in STI control. About one fifth of countries reported syphilis prevalence among key populations to GAM in 2016–2017.

The median reported syphilis seroprevalence for FSWs was 3.2%, in contrast to 6.0% for MSM. About 40% of the countries (15 out of 38) reported more than 5% prevalence among FSWs, and more than half of the countries (24/41) reported more than 5% prevalence of syphilis among MSM. More effort is needed to scale up programmes to increase the coverage of prevention and treatment services for these most-at-risk populations in order to reduce the burden of syphilis in the general population.

General population case reporting on urethral discharge and gonorrhoea

Case reporting indicators based on STI syndromes and etiological causes were incorporated into GAM in 2013. In 2016–2017, roughly 47% of countries globally (91 out of 194) reported either urethral discharge (UD) or gonorrhoea among men aged 15–49 years. Of these, 35 countries reported both indicators. Case rates varied widely within and across regions, and probably underestimate the burden of UD and gonorrhoea due to limitations and inconsistencies in reporting and diagnosis, as well as barriers to health-care-seeking behaviours. The median case rates per 100 000 men 15–49 years of age were:

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25446

